https://www.zacks.com/stock/news/2246921/moderna-mrna-posts-upbeat-data-from-next-gen-covid-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246921
Mar 27, 2024 - Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
zc:-455328472200432359
0
https://www.zacks.com/stock/news/2245553/bayer-bayry-banks-on-pipeline-progress-amid-challenges?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245553
Mar 25, 2024 - Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
zc:6930608402529022912
0
https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062
Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
zc:-3776330917213329406
0
https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568
Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
zc:-9033398220000923449
0
https://www.zacks.com/commentary/2241249/top-research-reports-for-microsoft-coca-cola-accenture?cid=CS-ZC-FT-research_daily-2241249
Mar 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Coca-Cola Company (KO) and Accenture plc (ACN).
zc:-1635427762309126316
0
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
zc:-4303199437016293624
0
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
zc:-406310911123861384
0
https://www.zacks.com/stock/news/2240265/pfizer-pfe-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2240265
Mar 13, 2024 - In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
zc:-1691411397383890598
0
https://www.fool.com/investing/2024/03/10/have-2000-2-magnificent-stocks-ready-for-a-bull-ru/?source=iedfolrf0000001
Mar 10, 2024 - These stocks are trading down, but investors may be overlooking some important points.
0
fool:1179558252830057673
0
https://www.fool.com/investing/2024/02/21/these-3-dividend-stocks-yield-more-than-5-but/?source=iedfolrf0000001
Feb 21, 2024 - Relying on payout ratio alone can sometimes give investors a misleading picture of just how safe a dividend payment is.
0
fool:5450555618918250316
0